Worldwide Clinical Trials appoints vp, Oncology Medical Affairs

Gerald Messerschmidt joins firm from Talon Therapeutics

Worldwide Clinical Trials, a US provider of clinical research services based in King of Prussia, PA, has appointed Gerald Messerschmidt as vice president, Oncology Medical Affairs.

Messerschmidt has more than 20 years’ clinical and operational leadership in the development of critical therapies for a multitude of oncology indications, the firm said. His portfolio of experience includes small molecules, biologic products, medical devices, genetic modification of living organisms and immune modulation therapy.

Prior to joining Worldwide Clinical Trials, Messerschmidt held the position of vp, Clinical Development at Talon Therapeutics (formerly Hana Biosciences) where he co-led the successful development of Marqibo, a new liposome plus vincristine product. From 2008–2010, Messerschmidt held senior positions within oncology at Onyx Pharmaceuticals and Icon Clinical Research, preceded by leading Wild-Type Enterprises as chairman and ceo from 2000–2008.

You may also like

Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Regulatory

Oncolytics Biotech announces positive clinical data for metastatic colorectal cancer trial

The latest results could accelerate the company's path to registration after the FDA's Breakthrough Therapy designations created momentum for companies advancing pioneering oncology platforms
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

From approval to access: the strategic role of packaging in drug launch success

In today’s increasingly complex pharmaceutical landscape, securing regulatory approval is only one milestone on the journey to market
Ingredients

FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars

The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
Regulatory

Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals

The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
Subscribe now